Entrada Therapeutics develops intracellular biologics using its proprietary Endosomal Escape Vehicle (EEV) platform to deliver oligonucleotide, antibody, enzyme, protein and peptide therapeutics. The company is advancing a diverse pipeline that includes several oligonucleotide programs for multiple neuromuscular diseases, led by Duchenne muscular dystrophy (DMD). Entrada plans to use the new funding to move its lead neuromuscular programs into clinical development and to expand the platform beyond neuromuscular diseases into additional therapeutic areas. The firm states its approach addresses challenges associated with both large and small molecule therapeutics and aims to transform treatment of devastating diseases. Entrada was initially funded and incubated within 5AM's 4:59 Initiative and has attracted participation from crossover and strategic investors. The company announced a $116 million Series B to support research and pipeline advancement. Entrada Therapeutics is a Boston-based biotechnology company focused on treating devastating diseases through the intracellular delivery of biologics. Its technology enables efficient intracellular delivery of proteins, peptides and nucleic acids, allowing development across several intracellular target classes. The company’s first application targets a rare, fatal mitochondrial disease caused by mutations in a gene that codes for an intracellular enzyme and currently has no approved treatments. The $59M Series A financing will allow Entrada to advance its lead program into human clinical trials. Entrada also plans to broaden its rare, monogenic disease pipeline by identifying and progressing additional intracellular enzyme replacement therapies. The company was funded and incubated within 5AM’s 4:59 Initiative via a seed investment from 5AM Ventures, Roche Venture Fund and MRLV. Leadership includes Dipal Doshi (President and CEO) and Natarajan Sethuraman, Ph.D. (Chief Scientific Officer).

Total raised

$175M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2021